Guide Calculator Compounds Blog Get Milligram
Healing Peptide

BPC-157

A 15-amino acid synthetic peptide derived from human gastric juice protein. Uniquely stable in gastric acid, BPC-157 is one of the few peptides observed in both injectable and oral protocols.

Moderate Evidence
30 min
Half-Life
95%
Bioavailability
250–500
mcg/day Typical
SubQ / Oral
Routes

Overview

Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide — a 15-amino acid sequence — originally isolated from human gastric juice. It is classified as a healing peptide due to the pharmacological interest surrounding its tissue-protective properties observed in preclinical models.

What distinguishes BPC-157 from most other peptides in common use is its remarkable stability in gastric acid. Most peptides degrade rapidly in the stomach's acidic environment, limiting them to injectable administration. BPC-157 retains structural integrity through the digestive tract, making it one of the rare peptides observed in both oral and subcutaneous protocols.

BPC-157 has a very short half-life of approximately 30 minutes, which positions it as a compound requiring daily administration in most observed protocols. Despite the rapid clearance, the peptide's pharmacokinetic profile supports consistent daily dosing to maintain tissue exposure.

Mechanism of Action

BPC-157's pharmacological activity has been studied across multiple pathways in preclinical research. The peptide's mechanisms are not fully characterized, but several key pathways have been identified in published literature:

Nitric Oxide System

BPC-157 has been observed to interact with the nitric oxide (NO) system in animal models, potentially influencing vasodilation and local blood flow dynamics at tissue level.

Growth Factor Modulation

Preclinical data suggest BPC-157 may influence the expression of growth factors involved in tissue repair processes, including VEGF (vascular endothelial growth factor) and FGF (fibroblast growth factor).

Gastric Acid Stability

Unlike most peptides that denature in acidic environments, BPC-157's amino acid sequence confers stability at low pH. This unique property is directly related to its origin as a fragment of a gastric juice protein, enabling oral bioavailability.

Pharmacokinetics

Understanding BPC-157's pharmacokinetic profile is essential for interpreting dosing frequency and route selection in observed protocols.

Parameter Value
Half-Life ~30 minutes
Bioavailability (SubQ) ~95%
Time to Peak ~30 minutes
Duration of Activity ~8 hours
Routes Subcutaneous, Oral
Molecular Weight 1,419.53 g/mol
Amino Acid Count 15

BPC-157's short half-life of approximately 30 minutes means that blood concentration peaks rapidly after subcutaneous injection and declines quickly. However, the duration of pharmacological activity (~8 hours) extends beyond what the half-life alone would suggest, indicating tissue-level activity that persists after circulating levels diminish.

The high subcutaneous bioavailability (~95%) means that nearly all of the injected peptide reaches systemic circulation. Oral bioavailability is lower but still notable for a peptide — a direct consequence of BPC-157's gastric acid stability.

Dosing Protocols

The following protocols represent commonly observed dosing patterns reported across the peptide community. These are observational summaries, not recommendations.

Standard Daily Protocol
Dose 250 mcg/day
Route Subcutaneous
Frequency Once daily
Duration 4–8 weeks
Higher-Dose Protocol
Dose 500 mcg/day
Route Subcutaneous
Frequency Once daily (or split 250 mcg 2x/day)
Duration 4–12 weeks
Oral Protocol
Dose 500 mcg/day
Route Oral (on empty stomach)
Frequency Once daily
Duration 4–12 weeks
Note Oral bioavailability is lower than SubQ

Reconstitution Steps

BPC-157 is supplied as a lyophilized (freeze-dried) powder and requires reconstitution before use. The following steps outline the standard preparation process.

  1. 1
    Gather Materials

    You'll need the BPC-157 vial (typically 5 mg), bacteriostatic water, an insulin syringe for drawing, and alcohol swabs for sterilization.

  2. 2
    Swab Both Vial Tops

    Clean the rubber stoppers on both the BPC-157 vial and bacteriostatic water vial with alcohol swabs. Allow to air dry briefly.

  3. 3
    Draw Bacteriostatic Water

    Draw 2 mL of bacteriostatic water into the syringe. With a 5 mg vial, this yields a concentration of 2,500 mcg/mL (each 10 units on an insulin syringe = 250 mcg).

  4. 4
    Add Water to Peptide Vial

    Insert the needle into the BPC-157 vial and slowly release the water along the inside wall of the vial. Do not spray directly onto the powder — let it run down the glass to preserve peptide integrity.

  5. 5
    Gently Swirl

    Once the water is added, gently swirl the vial until the powder is fully dissolved. Do not shake vigorously — peptides can denature with aggressive agitation. The solution should be clear.

  6. 6
    Store Properly

    Store the reconstituted vial in the refrigerator (2–8°C). Reconstituted BPC-157 with bacteriostatic water is generally stable for up to 4 weeks when refrigerated. Do not freeze reconstituted peptide.

Quick Reconstitution Math

5 mg vial + 2 mL bac water = 2,500 mcg/mL. For a 250 mcg dose, draw 10 units (0.1 mL) on a standard U-100 insulin syringe. Use the Milligram reconstitution calculator for custom vial sizes.

Frequently Asked Questions

What is the half-life of BPC-157?
BPC-157 has an estimated half-life of approximately 30 minutes. This short half-life means blood concentration levels drop relatively quickly after administration, which is why daily dosing protocols are commonly observed.
What is the typical BPC-157 dosage?
The most commonly reported BPC-157 dosage range is 250–500 mcg per day, administered via subcutaneous injection. Some protocols split this into two doses of 125–250 mcg, while others use a single daily administration.
Can BPC-157 be taken orally?
BPC-157 is uniquely stable in gastric acid, unlike most peptides that degrade in the stomach. This stability means both oral and injectable routes are observed in protocols. Oral bioavailability is lower than subcutaneous injection, though the peptide's gastric stability is one of its distinguishing pharmacokinetic properties.
How do you reconstitute BPC-157?
BPC-157 is typically reconstituted by adding bacteriostatic water to the lyophilized powder vial. A common preparation uses 2 mL of bacteriostatic water with a 5 mg vial, yielding a concentration of 2,500 mcg per mL. The water should be directed against the vial wall, not directly onto the powder.
How long do BPC-157 protocols typically last?
Common BPC-157 protocol durations range from 4 to 12 weeks. Given the peptide's short half-life and daily dosing frequency, consistent daily administration throughout the protocol duration is widely reported.
Should BPC-157 be injected near the target area?
Many users administer BPC-157 subcutaneously near the area of interest, though systemic subcutaneous injection (such as in the abdominal fat) is also commonly reported. The peptide enters systemic circulation regardless of injection site.

Track your protocol with Milligram

Real-time level tracking, dose reminders, and protocol analytics for 100+ compounds.

Download Milligram

Related Compounds

Related Reading